Hua Medicine Begins Phase I Trial of Novel Diabetes Treatment
publication date: Sep 6, 2013
Hua Medicine has begun a China Phase I clinical trial of a novel Glucokinase activator treatment for diabetes 2. The CFDA gave HMS5552, as the Hua drug is known, the designation of type 1.1 novel drug because no drug of the Glucokinase activator class has been approved anywhere in the world. Hua in-licensed China rights to the drug from Roche two years ago. In a statement, Dr. Li Chen, CEO of Hua Medicine, noted that it was a significant milestone for Hua to start clinical development in China of an innovative diabetes treatment that is intended for the world’s market. More details....
Stock Symbol: (SX: ROG)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.